莉芙敏对绝经期生殖道萎缩的改善作用

Efficacy of Remifemin on Postmenopausal Genital Atrophy

目的探讨莉芙敏改善绝经期妇女生殖道萎缩症状的疗效。方法选择绝经期生殖道萎缩患者112例,随机分为对照组和观察组,各56例。对照组患者采用戊酸雌二醇片治疗,观察组患者采用莉芙敏片治疗,疗程均为12周。结果治疗后,两组患者萎缩症状评分较治疗前均有降低,两组间降低程度未见明显差异(P>0.05);两组患者阴道健康评分均有提升(P<0.05),且观察组提升较对照组更显著(P<0.05);两组患者体内血清雌二醇含量均有升高,但对照组升高更显著(P<0.05);对照组子宫内膜厚度有所增厚(P<0.05),观察组未见明显改变(P>0.05)。对照组患者不良反应发生率显著高于观察组患者(P<0.05)。结论莉芙敏改善绝经期生殖道萎缩的疗效确切,且较传统激素替代治疗安全性更好。

Objective To detect the efficacy of remifemin on improving menopausal symptoms of genital atrophy. Methods 112 cases of patients with postmenopausal genital atrophy were randomly divided into control group and observation group, 56 cases in each group. The control group used Estradiol Valerate Tablets, the observation group were treated with Remifemin Tablets; the treatment for both groups lasted for 12 weeks. Results The atrophy symptom scores of the two groups were decreased compared with before treatment,and there was no significant difference between the two groups( P > 0. 05). The vaginal health scores of the two groups were improved( P < 0. 05),and the observation group improved more significantly( P < 0. 05). The serum estradiol content of the two groups were increased,but the control group increased more significantly( P < 0. 05). The endometrial thickness of the control group increased( P < 0. 05),and the observation group had no significant change( P > 0. 05). The occurrence rate of adverse reactions of the control group was significantly higher than those of the observation group( P < 0. 05). Conclusion Remifemin has clear effect on improving menopausal reproductive tract atrophy,and has good safety compared with the traditional hormone replacement therapy.